Alembic Pharmaceuticals Gets USFDA Nod To Market Generic Tablet For Atrial Fibrillation

The company has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for its medication in the strength of 400 mg.

Outlook Web Desk

Updated on: 10 January 2022 7:32 am

Getting your Trinity Audio player ready...

Alembic Pharmaceuticals Gets USFDA Nod To Market Generic Tablet For Atrial Fibrillation

Alembic Pharmaceuticals on Monday said it has received approval from the US health regulator to market generic Dronedarone tablets, which is used to reduce the risk of hospitalisation for atrial fibrillation, in the American market.

The company has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for its medication in the strength of 400 mg, the drugmaker said in a statement.

The tentatively approved ANDA is therapeutically equivalent to Sanofi-Aventis' Reference Listed Drug (RLD) product Multaq Tablets, 400 mg.

Dronedarone is indicated to reduce the risk of hospitalisation for atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation.

Cumulatively, the company has so far received 158 ANDA approvals from USFDA.